Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 19/20 | 0.65 |
| ▸ | BCHE | P06276 | 17/20 | 0.65 |
| ▸ | FAAH | O00519 | 1/20 | 0.57 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18306927 | 0.85 | ACHE (0.71) | ACHEBCHEFAAHMARK4 | |
| SCHEMBL12043574 | 0.85 | ACHE (0.71) | ACHEBCHEFAAHMARK4 | |
| SCHEMBL3203371 | 0.82 | ACHE (0.68) | ACHEBCHEFAAHMARK4 | |
| SCHEMBL1170430 | 0.82 | ACHE (0.68) | ACHEBCHEFAAHMARK4 | |
| SCHEMBL12043578 | 0.81 | ACHE (0.65) | ACHEBCHEFAAH | |
| SCHEMBL12043569 | 0.80 | ACHE (0.97) | ACHEBCHEFAAHMARK4 | |
| SCHEMBL29868287 | 0.80 | ACHE (0.97) | ACHEBCHEFAAHMARK4 | |
| Hydrochloric Acid SCHEMBL29634852 | 0.79 | ACHE (1.00) | ACHEBCHEFAAHMARK4 | |
| SCHEMBL18138876 | 0.79 | ACHE (0.75) | ACHEBCHEFAAHMARK4 | |
| SCHEMBL12590098 | 0.79 | ACHE (0.69) | ACHEBCHEFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012170599-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | ACHE 18/4885BCHE 42/4885FAAH 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.